IL153226A0 - Crystalline therapeutic agent - Google Patents

Crystalline therapeutic agent

Info

Publication number
IL153226A0
IL153226A0 IL15322601A IL15322601A IL153226A0 IL 153226 A0 IL153226 A0 IL 153226A0 IL 15322601 A IL15322601 A IL 15322601A IL 15322601 A IL15322601 A IL 15322601A IL 153226 A0 IL153226 A0 IL 153226A0
Authority
IL
Israel
Prior art keywords
therapeutic agent
crystalline therapeutic
crystalline
agent
therapeutic
Prior art date
Application number
IL15322601A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of IL153226A0 publication Critical patent/IL153226A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
IL15322601A 2000-07-28 2001-07-18 Crystalline therapeutic agent IL153226A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent
PCT/IB2001/001280 WO2002010171A1 (en) 2000-07-28 2001-07-18 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
IL153226A0 true IL153226A0 (en) 2003-07-06

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15322601A IL153226A0 (en) 2000-07-28 2001-07-18 Crystalline therapeutic agent

Country Status (46)

Country Link
EP (1) EP1305314B1 (xx)
JP (1) JP2004505087A (xx)
KR (1) KR100457937B1 (xx)
CN (1) CN1207297C (xx)
AP (1) AP1400A (xx)
AR (1) AR032628A1 (xx)
AT (1) ATE286901T1 (xx)
AU (2) AU7269001A (xx)
BG (1) BG107266A (xx)
BR (1) BR0112734A (xx)
CA (1) CA2417264C (xx)
CZ (1) CZ2003126A3 (xx)
DE (1) DE60108398T2 (xx)
DO (1) DOP2001000217A (xx)
DZ (1) DZ3364A1 (xx)
EA (1) EA004681B1 (xx)
EC (1) ECSP034454A (xx)
EE (1) EE200300045A (xx)
ES (1) ES2231521T3 (xx)
GE (1) GEP20053494B (xx)
HK (1) HK1055954A1 (xx)
HR (1) HRP20030061A2 (xx)
HU (1) HUP0302982A3 (xx)
IL (1) IL153226A0 (xx)
IN (1) IN2002MU01649A (xx)
IS (1) IS6626A (xx)
MA (1) MA26931A1 (xx)
MX (1) MX233602B (xx)
MY (1) MY117831A (xx)
NO (1) NO324220B1 (xx)
NZ (1) NZ523226A (xx)
OA (1) OA12337A (xx)
PA (1) PA8523501A1 (xx)
PE (1) PE20020277A1 (xx)
PH (1) PH12001001922B1 (xx)
PL (1) PL365133A1 (xx)
PT (1) PT1305314E (xx)
SK (1) SK572003A3 (xx)
SV (1) SV2001000570A (xx)
TN (1) TNSN01112A1 (xx)
TW (1) TWI285643B (xx)
UA (1) UA72631C2 (xx)
UY (1) UY26854A1 (xx)
WO (1) WO2002010171A1 (xx)
YU (1) YU4703A (xx)
ZA (1) ZA200301457B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
EP1620437B1 (en) 2003-04-29 2009-06-17 Pfizer Limited 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DK1742950T3 (da) 2004-04-07 2009-03-16 Pfizer Ltd Pyrazolo-[4,3-D]-pyrimidiner
EA012577B1 (ru) 2005-05-12 2009-10-30 Пфайзер Инк. БЕЗВОДНЫЕ КРИСТАЛЛИЧЕСКИЕ ФОРМЫ N-[1-(2-ЭТОКСИЭТИЛ)-5-(N-ЭТИЛ-N-МЕТИЛАМИНО)-7-(4-МЕТИЛПИРИДИН-2-ИЛАМИНО)-1Н-ПИРАЗОЛО[4,3-d]ПИРИМИДИН-3-КАРБОНИЛ]МЕТАНСУЛЬФОНАМИДА

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1073658E (pt) * 1998-04-20 2003-12-31 Pfizer Inibidores de ogmp pdes de pirazolopirimidinona para o tratamento da disfuncao sexual
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
PA8523501A1 (es) 2002-10-24
AP2001002234A0 (en) 2001-09-30
DZ3364A1 (fr) 2002-02-07
TNSN01112A1 (fr) 2005-11-10
CN1444585A (zh) 2003-09-24
AP1400A (en) 2005-04-28
NZ523226A (en) 2003-07-25
WO2002010171A1 (en) 2002-02-07
MY117831A (en) 2004-08-30
MX233602B (es) 2006-01-10
UA72631C2 (uk) 2005-03-15
BG107266A (bg) 2003-07-31
MXPA03000856A (es) 2003-06-06
GEP20053494B (en) 2005-04-25
UY26854A1 (es) 2002-02-28
JP2004505087A (ja) 2004-02-19
SK572003A3 (en) 2004-05-04
TWI285643B (en) 2007-08-21
AU2001272690B2 (en) 2005-12-08
EP1305314B1 (en) 2005-01-12
EE200300045A (et) 2004-12-15
PE20020277A1 (es) 2002-05-11
DOP2001000217A (es) 2002-10-30
EA200300079A1 (ru) 2003-06-26
HRP20030061A2 (en) 2003-04-30
OA12337A (en) 2006-05-15
PT1305314E (pt) 2005-04-29
CA2417264A1 (en) 2002-02-07
CN1207297C (zh) 2005-06-22
CA2417264C (en) 2007-06-12
PH12001001922B1 (en) 2006-11-21
IN2002MU01649A (xx) 2004-12-11
YU4703A (sh) 2006-01-16
BR0112734A (pt) 2004-08-10
ATE286901T1 (de) 2005-01-15
AR032628A1 (es) 2003-11-19
EA004681B1 (ru) 2004-06-24
NO20030416D0 (no) 2003-01-27
DE60108398D1 (de) 2005-02-17
CZ2003126A3 (cs) 2004-02-18
IS6626A (is) 2002-11-18
NO324220B1 (no) 2007-09-10
AU7269001A (en) 2002-02-13
HUP0302982A2 (hu) 2003-12-29
NO20030416L (no) 2003-02-05
ZA200301457B (en) 2004-04-28
HK1055954A1 (en) 2004-01-30
EP1305314A1 (en) 2003-05-02
HUP0302982A3 (en) 2005-01-28
MA26931A1 (fr) 2004-12-20
ES2231521T3 (es) 2005-05-16
KR100457937B1 (ko) 2004-11-20
ECSP034454A (es) 2003-03-10
SV2001000570A (es) 2002-09-03
DE60108398T2 (de) 2005-12-22
KR20030016430A (ko) 2003-02-26
PL365133A1 (en) 2004-12-27

Similar Documents

Publication Publication Date Title
GB0023983D0 (en) Therapeutic compounds
GB0008710D0 (en) Therapeutic compounds
GB0016681D0 (en) Therapeutic compounds
EP1296697A4 (en) THERAPEUTIC COMPOUNDS
GB0012671D0 (en) Therapeutic agents
GB0003397D0 (en) Therapeutic agents
GB0004003D0 (en) Therapeutic agents
GB0005789D0 (en) Therapeutic agents
GB0007907D0 (en) Therapeutic agents
GB0012214D0 (en) Therapeutic agents
GB0008696D0 (en) Therapeutic agents
GB0028583D0 (en) Therapeutic compounds
GB0000564D0 (en) Therapeutic agents
GB0007376D0 (en) Therapeutic agents
GB0030067D0 (en) Therapeutic agent
AU7269001A (en) Crystalline therapeutic agent
GB0013105D0 (en) Therapeutic compounds
SI1305314T1 (en) Crystalline therapeutic agent
GB0106464D0 (en) Crystalline therapeutic agent
GB0017049D0 (en) Therapeutic agent
GB0003767D0 (en) Therapeutic compounds
GB0013649D0 (en) Therapeutic compounds
GB0023985D0 (en) Therapeutic compounds
GB0023982D0 (en) Therapeutic Compounds
GB0022347D0 (en) Therapeutic compounds

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees